Further, we show that miR-205 can also regulate the phosphorylation/activation of MED1 through downregulating the HER3/PI3K/Akt pathway, thus inhibiting the recruitment of ER cofactors to the target gene promoters and regulating tamoxifen treatment response of breast cancer cells. The gene discussed is MED1; the disease is breast carcinoma.